ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO379

Anemia and Mortality in a Mexican PD Cohort

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Soto-Vargas, Javier, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • Velasco, Judith Jud, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • Parra Michel, Renato, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • Topete reyes, Jorge fernando, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • Pazarin-Villaseñor, Leonardo, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • García Cárdenas, Mario Alberto, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
  • Gutierrez-Prieto, Julio Alejandro, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Especialidad en Nefrologia, Hospital General Regional No 46 del IMSS, GUADALAJARA, JALISCO, Mexico
Background

The impact of anemia and its management on mortality is controversial in PD patients, despite of being considered and important part of the adequacy therapeutic plan, and the recommendations are based on evidence derived from HD patients. Thus, our aim was to study the association of anemia in all-cause mortality in a PD cohort.

Methods

During January 2012 to December 2017 we included 802 prevalent PD patients to investigate the impact of anemia (Hgb <10 g/dL) in all-cause mortality. We collected relevant information as demographic characteristics, anthropometric, biochemical, type (i.e. automatized PD or continuous ambulatory PD), dose of dialysis, peritoneal transport rate, as well as residual kidney function and comorbidities, and used them as covariates for a multivariate analysis.

Results

The median follow-up was 23 months (IQR 23-36.4). During the study period, there were 109 (13.6%) deaths. The median age was 47.9 years (IQR 28.3-64.4), 270 (33.7%) were female, and the main etiology of CKD was unknown in 383 (48.7%) patients, and T2D in 336 (42.7%), twenty (4.5%) had a previous kidney transplant, and 71 (14.5%) were initially on HD and then transferred to PD. The prevalence of anemia was 25.2% (202 patients), with a median Hgb level of 11 g/dL (IQR 9.7-12.0). In a binary logistic regression model adjusted for the variables afore mentioned, anemia was associated with all-cause mortality (OR 2.9 CI 95% 1.62-5.25 p<0.001), and this association was confirmed in a multivariate Cox regression (HR 2.5 CI 95% 1.6-4.2 p<0.001).

Conclusion

The presence of anemia is associated with a twofold increased risk for all-cause mortality in PD patients.

Cumulative survival in patients with and without anemia